Results 21 to 30 of about 202,668 (261)

MutS homologue hMSH5: role in cisplatin-induced DNA damage response

Molecular Cancer, 2012
Background Cisplatin (cis-diamminedichloroplatinum (II), CDDP) and its analogues constitute an important class of anticancer drugs in the treatment of various malignancies; however, its effectiveness is frequently affected by mutations in genes involved ...
Tompkins Joshua D, Wu Xiling, Her Chengtao   +2 more
doaj   +1 more source

PERBANDINGAN KEJADIAN LEUKOPENIA DAN TROMBOSITOPENIA PADA PENDERTIA KARSINOMA NASOFARING YANG MENDAPATKAN KEMOTERAPI PACLITAXEL CISPLATIN DAN CISPLATIN 5-FLUOROURACIL (5-FU)

Jurnal Kedokteran Diponegoro, 2019
Latar Belakang : Karsinoma Nasofaring (KNF) merupakan karsinoma yang muncul pada daerah nasofaring. Kemoterapi adalah segolongan obat-obatan yang dapat menghambat pertumbuhan kanker atau bahkan membunuh sel kanker.
Nadya Tara Audina, Willy Yusmawan, Zulfikar Naftali, Suprihati Suprihati   +3 more
doaj   +1 more source

Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage

Clinical and Translational Science, 2023
Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods.
Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa‐Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami, Keisuke Ishizawa   +13 more
doaj   +1 more source

Central Nervous System Neuroblastoma, FOXR2‐Activated: A Pooled Analysis of Published Clinical Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) neuroblastoma, FOXR2‐activated, is a recently recognized entity in the WHO CNS5 classification, defined by activation of the FOXR2 transcription factor and unique histopathological features. This review synthesizes available literature and pooled clinical data, providing insight into demographics ...
Sudarshawn Damodharan, Mohamed S. Abdelbaki   +1 more
wiley   +1 more source

Cisplatin Nephrotoxicity

American Journal of Kidney Diseases, 1986
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein, J, Winston, M, Goldstein, D, Moel, S, Dikman, J, Guttenplan   +5 more
openaire   +2 more sources

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Antioxidants, 2020
Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer ...
Wenyu Wang, Jihye Im, Soochi Kim, Suin Jang, Youngjin Han, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran, Yong Sang Song   +8 more
doaj   +1 more source

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan, Lindsay A. Renfro, Yue Wu, Katia M. Crisler, Erin Marcotte, Tanya Trippett, Terzah Horton, Bradford S. Hoppe, Frank G. Keller, Chris Forlenza, Cindy Schwartz, Kara M. Kelly, Peter D. Cole, Sharon M. Castellino, Justine M. Kahn   +14 more
wiley   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan, Michael Abele, Calogero Virgone, Michaela Kuhlen, Ricardo Lopez‐Almarez, Tal Ben‐Ami, Ewa Bien, Maja Cesen, Malgorzata A. Krawczyk, Andrea Ferrari, Gianni Bisogno, Yves Reguerre, Dominik T. Schneider, Louise Galmiche, Jorg Fuchs, Sarah Braungart, Bilgehan Yalcin, Ines B. Brecht, Daniel Orbach   +18 more
wiley   +1 more source

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source